Work

Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?

Year: 2019

Type: article

Abstract: Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide, with more than half a million new cases every year (1). Over half of these originate from the Asia Pacific region, where HNSCC accounts for a much greater proportion of newly diagnosed cancers (2). While the annual incidence of HNSCC in North America and Europe ranges from 5–10% of new cancer cases, this figure may be as high as 37.5% in some areas of Asia (3).

Source: Annals of Translational Medicine

DOI: 10.21037/atm.2019.01.46

Authors: Wenda Ye, Nicole C. Schmitt

Institutions: National Institutes of Health, Cleveland Clinic Lerner College of Medicine, National Institute on Deafness and Other Communication Disorders, Johns Hopkins University

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W2914620655

FWCI: 0.185

Cites: 18

Cited by: 2

Related to: 10